The impact of synthetic biology and collaboration in pharma

<p>This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “<a href= "https://www.ddw-online.com/why-synthetic-biology-is-the-next-big-thing-for-biopharma-15377-202211/">Why synthetic biology is the next big thing for biopharma</a>” and “<a href= "https://www.ddw-online.com/collaborative-spirit-helps-drive-innovation-15385-202202/">Collaborative spirit helps drive innovation</a>”.</p> <p>'Can synthetic biology save us?’ and ‘Synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. In the first article, Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential that synthetic biology holds within the drug discovery sector.</p> <p>In the second article, Dr David Walt, a professor at Harvard Medical School who runs labs at both Brigham and Women’s Hospital and the Wyss Institute at Harvard University, shares his thoughts on the drug discovery industry and what the pandemic has taught us about lab automation. This featured in this issue’s SLAS 2022 supplement.</p>